Skip to main content

Team explores diabetes drug’s ability to treat RSV infection

by Jul. 12, 2018, 9:31 AM

A drug used to treat diabetes may point to new therapies for respiratory syncytial virus (RSV) bronchiolitis — inflammation and obstruction of the lungs’ small airways. A multi-disciplinary team of Vanderbilt investigators has demonstrated that liraglutide reduces the inflammatory response to RSV infection in a mouse model of the disease.

The findings were reported in the Journal of Allergy and Clinical Immunology

Liraglutide is one of six “GLP-1R agonists” approved to treat type 2 diabetes. These drugs enhance insulin secretion from the pancreas by activating the glucagon-like peptide 1 receptor (GLP-1R).

KEEP READING »

Upcoming Events

MORE EVENTS »